CXCL12 and ovarian carcinoma: However, it is notable that the same correlations have been seen with other anti-VEGF agents in patients with brain, rectal, and liver cancer (for plasma SDF1α), and in patients with brain, rectal and ovarian cancer (for plasma PlGF) [32], [35], [36], [37], [38], [39].